Increased eyelid pigmentation associated with use of latanoprost

American Journal of Ophthalmology

Volumn 129, Issue 6, 2000, Pages 804-806

  Kook, Michael S ^a   Lee, Keunjang ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; DORZOLAMIDE; LATANOPROST;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DRUG WITHDRAWAL; EYE IRRITATION; EYE PHOTOGRAPHY; EYELID DISEASE; FEMALE; GLAUCOMA; HUMAN; PIGMENT DISORDER; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; EYELID DISEASES; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MIDDLE AGED; PIGMENTATION DISORDERS; PROSTAGLANDINS F, SYNTHETIC; SKIN PIGMENTATION;

EID: 0033864298     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(00)00402-5     Document Type: Article

References (4)

1. Alm A., Camras C., Watson P. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 41:(suppl 2):1997;S105-S110.
2. Camras C.B., Alm A., Watson P., Stjernschantz J. The Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology. 103:1996;1916-1924.
3. Papas R.M., Pusin S., Hissibotham E.J. Evidence of early change in iris color with latanoprost use. Arch Ophthalmol. 116:1998;1115-1116.
4. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 41:(suppl 2):1997;S129-S138.